Simultaneous FAPI PET/MRI Targeting the Fibroblast-Activation Protein for Breast Cancer.

Background Integrated PET/MRI is a promising modality for breast assessment. The most frequently used tracer, fluorine 18 (18F) fluorodeoxyglucose (FDG), is applied for whole-body staging in advanced breast cancer but has limited accuracy in evaluating primary breast lesions. The fibroblast-activation protein (FAP) is abundantly expressed in invasive breast cancer. FAP-directed PET tracers have recently become available, but results in primary breast tumors remain lacking. Purpose To evaluate the use of FAP inhibitor (FAPI) breast PET/MRI in assessing breast lesions and of FAPI whole-body scanning for lymph node (LN) and distant staging using the ligand gallium 68 (68Ga)-FAPI-46. Materials and Methods In women with histologically confirmed invasive breast cancer, all primary 68Ga-FAPI-46 breast and whole-body PET/MRI and PET/CT examinations conducted at the authors' center between October 2019 and December 2020 were retrospectively analyzed. MRI lesion characteristics and standardized uptake values (SUVs) were quantified with dedicated software. Mann-Whitney U tests were used to compare tumor SUVs across different tumor types. The Pearson correlation coefficient was calculated between SUV and measures of MRI morphologic characteristics. Results Nineteen women (mean age, 49 years ± 9 [standard deviation]) were evaluated-18 to complement initial staging and one for restaging after therapy for distant metastases. Strong tracer accumulation was observed in all 18 untreated primary breast malignancies (mean maximum SUV [SUVmax] = 13.9 [range, 7.9-29.9]; median lesion diameter = 26 mm [range, 9-155 mm]), resulting in clear tumor delineation across different gradings, receptors, and histologic types. All preoperatively verified LN metastases in 13 women showed strong tracer accumulation (mean SUVmax= 12.2 [range, 3.3-22.4]; mean diameter = 21 mm [range, 14-35 mm]). Tracer uptake established or supported extra-axillary LN involvement in seven women and affected therapy decisions in three women. Conclusion This retrospective analysis indicates use of 68Ga fibroblast-activation protein inhibitor tracers for breast cancer diagnosis and staging. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Mankoff and Sellmyer in this issue.

[1]  Hua Wu,et al.  Comparison of 68Ga-FAPI and 18F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers. , 2020, Radiology.

[2]  M. Yadav,et al.  Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  G. Hospers,et al.  Application of PET Tracers in Molecular Imaging for Breast Cancer , 2020, Current Oncology Reports.

[4]  A. Stang,et al.  Impact of 18F-FDG PET/MR on therapeutic management in high risk primary breast cancer patients - A prospective evaluation of staging algorithms. , 2020, European journal of radiology.

[5]  A. Stang,et al.  Prospective evaluation of whole-body MRI and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  L. Moy,et al.  Axillary Nodal Evaluation in Breast Cancer: State of the Art. , 2020, Radiology.

[7]  Danny F. Martinez,et al.  Multiparametric 18F-FDG PET/MRI of the Breast: Are There Differences in Imaging Biomarkers of Contralateral Healthy Tissue Between Patients With and Without Breast Cancer? , 2019, The Journal of Nuclear Medicine.

[8]  R. Mann,et al.  Breast MRI: State of the Art. , 2019, Radiology.

[9]  Frederik L. Giesel,et al.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer , 2019, The Journal of Nuclear Medicine.

[10]  D. Axelrod,et al.  PET/MRI in Breast Cancer , 2018, Journal of magnetic resonance imaging : JMRI.

[11]  D. Jäger,et al.  A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts , 2018, The Journal of Nuclear Medicine.

[12]  Thomas Lindner,et al.  Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein , 2018, The Journal of Nuclear Medicine.

[13]  H. Quick,et al.  Local and whole-body staging in patients with primary breast cancer: a comparison of one-step to two-step staging utilizing 18F-FDG-PET/MRI , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  D. Narayanan,et al.  Dedicated Breast Gamma Camera Imaging and Breast PET: Current Status and Future Directions. , 2018, PET clinics.

[15]  M. Gönen,et al.  Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  E. Puré,et al.  Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer. , 2013, Human pathology.

[17]  D. Groheux,et al.  Performance of FDG PET/CT in the clinical management of breast cancer. , 2013, Radiology.

[18]  Li-Na Yu,et al.  Expression and role of fibroblast activation protein-alpha in microinvasive breast carcinoma , 2011, Diagnostic pathology.

[19]  M. Plana,et al.  Magnetic resonance imaging in the preoperative assessment of patients with primary breast cancer: systematic review of diagnostic accuracy and meta-analysis , 2011, European Radiology.

[20]  E. Rutgers,et al.  Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. , 2010, European journal of cancer.